We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 511

Dispelling the Myriad gene patent harmonization myth

  • Foley & Lardner LLP
  • -
  • Australia, Canada, European Union, France, Germany, Japan, USA
  • -
  • April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the

IP monitor - patenting the correct dosage: new Patent Office guidelines difficult to swallow

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • June 18 2013

On June 10, 2013, the Canadian Intellectual Property Office (CIPO)1 issued a guidance document for patent examiners (the "Notice") on examining

Court bifurcates determination of Start Date for section 8 action

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 30 2014

This is an action commenced pursuant to section 8 of the Patented Medicines (Notice of Compliance) Regulations. Pfizer counterclaimed against Apotex

Canada: Federal Court prohibits the approval of generic Anastrozole ARIMIDEX

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • September 12 2011

On August 29, 2011 the Federal Court allowed an application by AstraZeneca Canada Inc. and AstraZeneca UK Limited (collectively “AstraZeneca”) pursuant to section 6 of the Patented Medicines (Notice of Compliance) Regulations, for an order prohibiting the Minister of Health from issuing a Notice of Compliance to Mylan Pharmaceuticals ULC (“Mylan”) in respect of its generic version of the drug anastrozole until after the expiry of Canadian Patent No. 1,337,420 (the “’420 Patent”

Federal Court grants injunction that allows infringing biologic drug to stay on the market

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • June 20 2014

Case: AbbVie Corporation, AbbVie Deutschland GMBH & Co. KG and AbbVie Biotechnology Ltd. v. Janssen Inc., 2014 FC 489 Drug: Ustekinumab (STELARA®

Federal Court of Appeal refuses to strike pleading of patent infringement ZYMAR (gatifloxacin)

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • April 27 2011

On April 14, 2011, the Federal Court of Appeal dismissed an appeal by Apotex Inc. and Apotex Pharmachem Inc. ("Apotex") from an order dismissing its motion to strike the statement of claim filed by Allergan, Inc., Allergan Sales, LLC, Allergan USA, Inc. and Kyorin Pharmaceutical Co., Ltd ("Allergan") in a patent infringement action

Federal court prohibits the approval of a generic prodrug CELLCEPT (mycophenolate mofetil)

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • July 26 2011

On July 13, 2011, the Federal Court allowed an application by Hoffman La-Roche Limited (“Roche”), pursuant to section 6 of the Patented Medicines (Notice of Compliance) Regulations, for an order prohibiting the Minister of Health from issuing a Notice of Compliance to Apotex Inc. (“Apotex”) in respect of its generic version of the drug mycophenolate mofetil (“MMF”) until after the expiry of Canadian Patent No. 1,333,285 (the “285 Patent”

Bristol-Myers Squibb obtains order of prohibition against Mylan regarding efavirenz

  • Smart & Biggar/Fetherstonhaugh
  • -
  • Canada
  • -
  • October 5 2012

On September 27, 2012, Justice Barnes of the Federal Court granted Bristol-Myers Squibb ("BMS") an Order prohibiting the Minister of Health from issuing a notice of compliance ("NOC") to Mylan Pharmaceuticals ULC for a generic efavirenz product (BMS's SUSTIVA) until the expiry of Patent No. 2,101,572 (’572), but not Patent No. 2,279,198 (’198

USPTO issues new subject matter guidance post-Myriad and Prometheus

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • March 7 2014

The United States Patent and Trademark Office (USPTO) issued a new guidance document for Examiners on March 4, 2014, effective immediately

Biosimilar monoclonal antibodies emerge from the pipeline on both sides of the Atlantic

  • Bereskin & Parr LLP
  • -
  • Canada, European Union
  • -
  • March 7 2014

The European Medicines Agency ("EMEA") made its biosimilar monoclonal antibody guidelines effective in December 20121. Less than a year later, in